A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Exclusion Criteria

• •Leptomeningeal disease as the only manifestation of the current malignancy
• •History of Type 1 or 2 diabetes mellitus requiring regular medication
• •Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytics
• •Inability or unwillingness to swallow pills
• •Malabsorption syndrome or other condition that would interfere with enteral absorption
• •Known untreated CNS malignancies or treated brain metastases that are not radiographically stable for \>= 3 months
• •Congenital long QT syndrome or QTc \> 500 msec, as determined by at least two of the three baseline ECG measurements
• •Active congestive heart failure or ventricular arrhythmia requiring medication
• •Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
• •Active infection requiring intravenous (IV) antibiotics
• •Patients requiring any daily supplemental oxygen
• •DLco, 50% predicted value corrected for AV and Hgb prior to initiation of study treatment
• •Uncontrolled hypomagnesemia or hypokalemia, defined as values below the lower limit of normal (LLN) or hypercalcemia above the ULN for the institution despite adequate electrolyte supplementation or management
• •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
• •Known human immunodeficiency virus (HIV) infection
• •Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patients at high risk from treatment complications
• •Significant traumatic injury within 3 weeks before Day 1
• •Major surgical procedure within 4 weeks prior to initiation of study treatment
• •Prior allogeneic hematopoietic stem cell transplantation (HSCT) at any time or autologous HSCT within 12 weeks of study entry
• •Treatment with chemotherapy, hormonal therapy (except GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, or radiation therapy (except palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment (exceptions are kinase inhibitors that are approved by the local regulatory authorities, which may be used within 2 weeks prior to initiation of study treatment, provided that any drug-related toxicity has completely resolved and after approval by the Medical Monitor has been granted)
• •Palliative radiation to bony metastases within 2 weeks prior to initiation of study treatment
• •Need for chronic corticosteroid therapy
• •Treatment with an investigational agent within 4 weeks prior to initiation of study treatment
• •Unresolved toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy
• •Pregnancy or lactation
• •Inability to comply with study and follow-up procedures
• •For patients eligible to participate in Stage 2 DCE-MRI and MRS assessments, any contraindication to MRI examination, including the following:
• •Imbedded metallic material/devices (metal implants or large tattoos in the field of view)
• •Severe claustrophobia
• •Physical characteristics (weight or size) that exceed the capabilities of the MRI scanner
• •Known allergy or hypersensitivity reactions to gadolinium, verse